After all that effort with alpha-blockers, beta-blockers, ACE inhibitors, etc....are we just going to circle back to diuretics?? Will Eli Lilly fork over $1,000,000,000 to make Zyprexa marketing …
Pharma News 11_9
A huge week for news, especially on the cardiovascular front: Prasugrel, the Lilly/Daiichi-Sankyo blood thinner, was the biggest headline grabber. This potential blockbuster came in with mixed …